Windward Bio
Basel
About Windward Bio
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $200.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2025)
- Website: windwardbio.com
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/windward-bio-59592 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.